HR Execs on the Move


 
At Athira, we aim to restore neuronal health for those suffering from neurological diseases, including Alzheimer`s, so that patients can regain their memories, lives, and family relationships. We are a motivated, impassioned team committed to making a positive impact on human health.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.athira.com
  • 18706 North Creek Parkway Suite 104
    Bothell, WA USA 98011
  • Phone: 866.725.0930

Executives

Name Title Contact Details
Andrew Gengos
Chief Financial Officer and Chief Business Officer Profile
Leen Kawas
Chief Executive Officer Profile

Similar Companies

Almirall

With over 1,975 employees, it has a presence, through its 13 affiliates in Europe and United States.

Acerus Pharmaceuticals

Acerus Pharmaceuticals Corporation is a Canadian-based specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve patient experience, with a primary focus in the field of men`s and women`s health. The Company commercializes its products via its own salesforce in Canada, and through a global network of licensed distributors in the U.S. and other territories.

BCM GROUP

BCM GROUP is a Hamburg, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pro Med Pharmacies

Pro Med Pharmacies, Inc is a Amarillo, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

ProMetic

ProMetic Life Sciences Inc. (www.prometic.com) is a long established biopharmaceutical company with globally recognized expertise in bioseparation, plasma-derived therapeutics and small-molecule drug development. ProMetic offers its state of the art technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order to develop best-in-class therapeutics and orphan drugs. ProMetic is also active in developing its own novel small-molecule therapeutic products targeting unmet medical needs in the field of fibrosis, anemia, neutropenia, cancer and autoimmune diseases/inflammation as well as certain nephropathies. Headquartered in Laval (Canada), ProMetic has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and commercial activities in the U.S., Europe, Russia, Australia and Asia.